IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER

Carcinoma, Non-Small-Cell Lung

Zhonglin Haomonoclonal_antibodyPhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 48/ 100
Competitive Position: 65/ 100

Competitive context

1206 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Onartuzumab Hoffmann-La Roche	Phase 3	BBB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:

Recurrent Adult Burkitt LymphomaDormant

BBB

Indicative ·

78 / 100

View asset →

Recurrent Adult Diffuse Small Cleaved Cell LymphomaDormant

BBB

Indicative ·

76 / 100

View asset →

lymphoblastic lymphomaDormant

BBB